

(Print or Type Responses)

1. Name and Address of Reporting Person* McWilliams David		2. Issuer Name and Ticker or Trading Symbol Greenwich LifeSciences, Inc. [GLSI]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> 10% Owner <input type="checkbox"/> Other (specify below)					
(Last) (First) (Middle) C/O GREENWICH LIFESCIENCES, INC., 3992 BLUEBONNET DR., BUILDING 14		3. Date of Earliest Transaction (Month/Day/Year) 09/29/2020							
(Street) STAFFORD, TX 77477		4. If Amendment, Date Original Filed(Month/Day/Year)		6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person					
(City) (State) (Zip)		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price		
Common Stock	09/29/2020		M		152,604	A	(1)	599,583	D
Common Stock	09/29/2020		M		7,663	A	(2)	607,246	D
Common Stock	09/29/2020		M		3,746	A	(3)	610,992	D
Common Stock	09/29/2020		M		7,609	A	(4)	618,601	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(1)	09/29/2020		M			152,604	(1)	(1)	Common Stock	152,604	\$ 0	0	D	
Series B Preferred Stock	(2)	09/29/2020		M			7,663	(2)	(2)	Common Stock	7,663	\$ 0	0	D	
Series C Preferred Stock	(3)	09/29/2020		M			3,746	(3)	(3)	Common Stock	3,746	\$ 0	0	D	
Series D Preferred Stock	(4)	09/29/2020		M			6,555	(4)	(4)	Common Stock	6,555	\$ 0	0	D	
Series D Preferred Stock	(5)	09/29/2020		J	(6)		1,054	(5)	(5)	Common Stock	1,054	\$ 0	1,054	D	
Series D Preferred Stock	(4)	09/29/2020		M			1,054	(4)	(4)	Common Stock	1,054	\$ 0	0	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other

McWilliams David C/O GREENWICH LIFESCIENCES, INC. 3992 BLUEBONNET DR., BUILDING 14 STAFFORD, TX 77477	X			
--	---	--	--	--

Signatures

/s/ David McWilliams		09/30/2020
<small>**Signature of Reporting Person</small>		<small>Date</small>

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Series A Preferred Stock converted into Issuer common stock on a 1-for-1 basis and had no expiration date.
- (2) The Series B Preferred Stock converted into Issuer common stock on a 1-for-1 basis and had no expiration date.
- (3) The Series C Preferred Stock converted into Issuer common stock on a 1-for-1 basis and had no expiration date.
- (4) The Series D Preferred Stock converted into Issuer common stock on a 1-for-1 basis and had no expiration date.
- The Series D Preferred Stock have no expiration date and are convertible, at the option of the holder, into shares of common stock of the Issuer at the then-effective conversion rate for no
- (5) additional consideration (subject to the payment of cash, if applicable, in lieu of any fractional shares in accordance with the Issuer's Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation").
- (6) The Reporting Person was issued additional shares of Series D Preferred Stock in connection with the Issuer's initial public offering as a result of the anti-dilution protection provisions set forth in the Issuer's Certificate of Incorporation.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.